These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1177741)

  • 21. [Therapeutic effect of pyridylcarbinolic ester of clofibric acid on the changes of the lipid and fibrinolytic picture in arteriosclerotic patients].
    Rugginenti
    Minerva Med; 1974 May; 65(35):1906-16. PubMed ID: 4601840
    [No Abstract]   [Full Text] [Related]  

  • 22. [Potentiation by clofibride of the heparin-induced clearing reaction (intravascular hydrolysis of neutral lipids), in hyperlipemic rabbits].
    Elsair J; Marquie G; Drif M; Khelfat K; Benouniche N; Tabet Aoul M; Tabet Aoul FS; Iklef F; Ghouini A
    C R Seances Soc Biol Fil; 1982; 176(2):140-5. PubMed ID: 6212098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)].
    Schneider J; Mühlfellner G; Mühlfellner O; Hausmann L; Schubotz R
    Arzneimittelforschung; 1980; 30(11b):2059-62. PubMed ID: 7194060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential hypolipidemic agents. 8. 2-Chloro-5-piperidinosulphono-3-thiophenecarboxylic acids.
    Dafgård B; Gronowitz S; Bondesson G; Magnusson O; Stjernström NE
    Acta Pharm Suec; 1974 Jun; 11(3):309-12. PubMed ID: 4839741
    [No Abstract]   [Full Text] [Related]  

  • 25. Anticholesterolemic effect of 3,4-di(OH)-phenylpropionic amides in high-cholesterol fed rats.
    Kim SJ; Bok SH; Lee S; Kim HJ; Lee MK; Park YB; Choi MS
    Toxicol Appl Pharmacol; 2005 Oct; 208(1):29-36. PubMed ID: 16164959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Reduction of serum triglycerides with a combined application of butylbiguanide and clofibrate in animal experiments].
    Beckmann VR
    Arzneimittelforschung; 1975 May; 25(5):775-6. PubMed ID: 1242321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of colestipol resin and of colestipol plus clofibrate on the turnover of plasma cholesterol in man.
    Goodman DS; Noble RP; Dell RB
    J Clin Invest; 1973 Oct; 52(10):2646-55. PubMed ID: 4729058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The treatment of hypertriglyceridemia].
    Wollenweber J
    ZFA (Stuttgart); 1978 Feb; 54(6):349-53. PubMed ID: 636529
    [No Abstract]   [Full Text] [Related]  

  • 29. [Hypolipidemic activity of glycine and its derivatives].
    Ryzhenkov VE; Molokovskiĭ DS; Ioffe DV
    Vopr Med Khim; 1984; 30(2):78-80. PubMed ID: 6740998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipid lowering influence of ethyl p-chlorophenoxyisobutyrate in liver of rats fed high fat diets.
    Kokatnur MG; Malcom GT
    Metabolism; 1970 Feb; 19(2):120-8. PubMed ID: 5410942
    [No Abstract]   [Full Text] [Related]  

  • 31. [Action of simfibrate on post-heparin lipoprotein lipase].
    Cavallini L; Lucchetti G; Marchi S; Guglielmini R
    Clin Ter; 1980 Jan; 92(1):25-31. PubMed ID: 7004746
    [No Abstract]   [Full Text] [Related]  

  • 32. Studies on antihyperlipidemic agents. I. Synthesis and hypolipidemic activities of phenoxyphenyl alkanoic acid derivatives.
    Kawamatsu Y; Saraie T; Imamiya E; Nishikawa K; Hamuro Y
    Arzneimittelforschung; 1980; 30(3):454-9. PubMed ID: 7387754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypolipidemic activity of Indan--1--acetic acids.
    Adak M; Gupta JK
    Nepal Med Coll J; 2006 Mar; 8(1):22-6. PubMed ID: 16827085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and hypolipidemic evaluation of beta-alkylaminopropiophenone and beta-alkylaminopropio-2'-naphthone derivatives in rodents.
    Huang Y; Hall IH
    Pharmazie; 1996 Apr; 51(4):199-206. PubMed ID: 8628737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Comparative biochemical and ultrastructural study of the hepatic response induced in the rat by 2 hypolipemic agents: clofibrate and itanoxone].
    Gendre PM; Marcelon G; Delhon A; Lauressergues H; Fauran F
    J Pharmacol; 1984; 15(2):209-22. PubMed ID: 6738078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipid lowering effects on cardiovascular morbidity and mortality. Clinical evidence and therapeutic guidelines.
    Islami Y; Ribeiro LG
    Arq Bras Cardiol; 1988 Jul; 51(1):43-8. PubMed ID: 3073735
    [No Abstract]   [Full Text] [Related]  

  • 37. The hypolipidemic effect of a new ACAT inhibitor, VULM 1457, in diabetic-hypercholesterolaemic rats.
    Adameová A; Kuzelová M; Faberová V; Svec P
    Pharmazie; 2005 Sep; 60(9):714-5. PubMed ID: 16222877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
    Naruszewicz M; Nowicka G; Szostak WB; Kłosiewicz-Latoszek L
    Kardiol Pol; 1982; 25(7-8):527-31. PubMed ID: 7169740
    [No Abstract]   [Full Text] [Related]  

  • 39. Hypolipidemic activity of some derivatives of 6H-dibenzo[b,d]pyran.
    Banzatti C; Branzoli U; Lovisolo PP; Melloni P; Orsini G; Salvadori P
    Arzneimittelforschung; 1984; 34(8):864-9. PubMed ID: 6541922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacology of fenofibrate (author's transl)].
    Kritchevsky D
    Nouv Presse Med; 1980 Dec; 9(49):3769-73. PubMed ID: 7208345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.